| At Home Healthcare | |
| 177 Craft Drive, Suite 100, Alamosa, Colorado 81101 | |
| (719) 589-6425 | |
| Name | At Home Healthcare |
|---|---|
| Location | 177 Craft Drive, Suite 100, Alamosa, Colorado |
| Certified By | Medicare |
| Services Offered | Nursing Care Physical Therapy Occupational Therapy Medical Social Services Home Health Aide |
| Medicare ID | 67248 |
| Ownership Type | Proprietary |
| Service Area Zip Codes | 81101, 81120, 81123, 81124, 81125, 81126, 81131, 81132, 81133, 81136, 81138, 81140, 81141, 81143, 81144, 81146, 81148, 81149, 81151, 81152, 81154 |
| NPI Number | 1043200348 |
| Organization Name | LIFE CARE AT HOME OF COLORADO INC. |
| Doing Business As | AT HOME HEALTHCARE, INC. |
| Address | 177 Craft Drive, Suite 100, Alamosa, CO 81101 |
| Phone Number | 719-589-6425 |
News Archive
PAREXEL Consulting, a business unit of PAREXEL International (Nasdaq: PRXL) and a leading global life sciences consultancy serving the biopharmaceutical and medical device industries, today released its second annual study on the state of the U.S. Food and Drug Administration (FDA) drug review process.
Taking aim at the fundamental biology of cancer cells, the National Institutes of Health has awarded $747,000 to Worcester Polytechnic Institute for a three-year research project to explore the molecular mechanisms associated with the genetic mutations and chromosome instability observed in all cancer cells.
HealthLeaders-InterStudy, a provider of managed care industry intelligence, reports hordes of area physicians are venturing enthusiastically into ownership of general acute-care hospitals with the vow to treat a full range of patients.
Early results from a UCLA-led clinical trial found treating women with estrogen receptor (ER)-positive and human epidermal growth factor receptor-2 (HER2)-negative early breast cancers with a novel type of anti-hormonal therapy, called an oral selective estrogen receptor degrader (SERD), led to clinically meaningful reductions in tumor activity prior to surgery.
› Verified 6 days ago
| NPI Number | 1235545997 |
| Organization Name | LHCG LVII, LLC |
| Doing Business As | AT HOME HEALTHCARE |
| Address | 177 Craft Dr, Ste 100, Alamosa, CO 81101 |
| Phone Number | 719-589-6425 |
News Archive
PAREXEL Consulting, a business unit of PAREXEL International (Nasdaq: PRXL) and a leading global life sciences consultancy serving the biopharmaceutical and medical device industries, today released its second annual study on the state of the U.S. Food and Drug Administration (FDA) drug review process.
Taking aim at the fundamental biology of cancer cells, the National Institutes of Health has awarded $747,000 to Worcester Polytechnic Institute for a three-year research project to explore the molecular mechanisms associated with the genetic mutations and chromosome instability observed in all cancer cells.
HealthLeaders-InterStudy, a provider of managed care industry intelligence, reports hordes of area physicians are venturing enthusiastically into ownership of general acute-care hospitals with the vow to treat a full range of patients.
Early results from a UCLA-led clinical trial found treating women with estrogen receptor (ER)-positive and human epidermal growth factor receptor-2 (HER2)-negative early breast cancers with a novel type of anti-hormonal therapy, called an oral selective estrogen receptor degrader (SERD), led to clinically meaningful reductions in tumor activity prior to surgery.
› Verified 6 days ago
| Quality Rating: |
News Archive
PAREXEL Consulting, a business unit of PAREXEL International (Nasdaq: PRXL) and a leading global life sciences consultancy serving the biopharmaceutical and medical device industries, today released its second annual study on the state of the U.S. Food and Drug Administration (FDA) drug review process.
Taking aim at the fundamental biology of cancer cells, the National Institutes of Health has awarded $747,000 to Worcester Polytechnic Institute for a three-year research project to explore the molecular mechanisms associated with the genetic mutations and chromosome instability observed in all cancer cells.
HealthLeaders-InterStudy, a provider of managed care industry intelligence, reports hordes of area physicians are venturing enthusiastically into ownership of general acute-care hospitals with the vow to treat a full range of patients.
Early results from a UCLA-led clinical trial found treating women with estrogen receptor (ER)-positive and human epidermal growth factor receptor-2 (HER2)-negative early breast cancers with a novel type of anti-hormonal therapy, called an oral selective estrogen receptor degrader (SERD), led to clinically meaningful reductions in tumor activity prior to surgery.
› Verified 6 days ago
| Quality Measure | Provider | National Avg. |
|---|---|---|
| How often the home health team began their patients’ care in a timely manner | 98.1 | 95.7 |
| How often the home health team taught patients (or their family caregivers) about their drugs | 99.7 | 98.6 |
| How often the home health team checked patients’ risk of falling | 100 | 99.6 |
| How often the home health team checked patients for depression | 98.6 | 97.4 |
| How often the home health team made sure that their patients have received a flu shot for the current flu season. | 82.1 | 78.7 |
| How often the home health team made sure that their patients have received a pneumococcal vaccine (pneumonia shot). | 88.1 | 82.2 |
| With diabetes, how often the home health team got doctor’s orders, gave foot care, and taught patients about foot care | 94.9 | 96.4 |
News Archive
PAREXEL Consulting, a business unit of PAREXEL International (Nasdaq: PRXL) and a leading global life sciences consultancy serving the biopharmaceutical and medical device industries, today released its second annual study on the state of the U.S. Food and Drug Administration (FDA) drug review process.
Taking aim at the fundamental biology of cancer cells, the National Institutes of Health has awarded $747,000 to Worcester Polytechnic Institute for a three-year research project to explore the molecular mechanisms associated with the genetic mutations and chromosome instability observed in all cancer cells.
HealthLeaders-InterStudy, a provider of managed care industry intelligence, reports hordes of area physicians are venturing enthusiastically into ownership of general acute-care hospitals with the vow to treat a full range of patients.
Early results from a UCLA-led clinical trial found treating women with estrogen receptor (ER)-positive and human epidermal growth factor receptor-2 (HER2)-negative early breast cancers with a novel type of anti-hormonal therapy, called an oral selective estrogen receptor degrader (SERD), led to clinically meaningful reductions in tumor activity prior to surgery.
› Verified 6 days ago
| Quality Measure | Provider | National Avg. |
|---|---|---|
| How often patients got better at walking or moving around | 84.5 | 79.6 |
| How often patients got better at getting in and out of bed | 88.2 | 81.1 |
| How often patients got better at bathing | 90.6 | 82.3 |
| How often patients’ breathing improved | 92.3 | 82.8 |
| How often patients’ wounds improved or healed after an operation | 90.6 | 92.3 |
| How often patients got better at taking their drugs correctly by mouth | 83 | 75 |
| How often home health patients had to be admitted to the hospital | 13.8 | 15.4 |
| How often patients receiving home health care needed urgent, unplanned care in the ER without being admitted | 16.3 | 13 |
| How often physician-recommended actions to address medication issues were completely timely | 96.9 | 94 |
News Archive
PAREXEL Consulting, a business unit of PAREXEL International (Nasdaq: PRXL) and a leading global life sciences consultancy serving the biopharmaceutical and medical device industries, today released its second annual study on the state of the U.S. Food and Drug Administration (FDA) drug review process.
Taking aim at the fundamental biology of cancer cells, the National Institutes of Health has awarded $747,000 to Worcester Polytechnic Institute for a three-year research project to explore the molecular mechanisms associated with the genetic mutations and chromosome instability observed in all cancer cells.
HealthLeaders-InterStudy, a provider of managed care industry intelligence, reports hordes of area physicians are venturing enthusiastically into ownership of general acute-care hospitals with the vow to treat a full range of patients.
Early results from a UCLA-led clinical trial found treating women with estrogen receptor (ER)-positive and human epidermal growth factor receptor-2 (HER2)-negative early breast cancers with a novel type of anti-hormonal therapy, called an oral selective estrogen receptor degrader (SERD), led to clinically meaningful reductions in tumor activity prior to surgery.
› Verified 6 days ago
| Question Type: | Rating by Patients |
|---|---|
| Health team gave care in a professional way | |
| Health team communicated well with them | |
| Health team discussed medicines, pain, and home safety | |
| How patients rated overall care from agency |
News Archive
PAREXEL Consulting, a business unit of PAREXEL International (Nasdaq: PRXL) and a leading global life sciences consultancy serving the biopharmaceutical and medical device industries, today released its second annual study on the state of the U.S. Food and Drug Administration (FDA) drug review process.
Taking aim at the fundamental biology of cancer cells, the National Institutes of Health has awarded $747,000 to Worcester Polytechnic Institute for a three-year research project to explore the molecular mechanisms associated with the genetic mutations and chromosome instability observed in all cancer cells.
HealthLeaders-InterStudy, a provider of managed care industry intelligence, reports hordes of area physicians are venturing enthusiastically into ownership of general acute-care hospitals with the vow to treat a full range of patients.
Early results from a UCLA-led clinical trial found treating women with estrogen receptor (ER)-positive and human epidermal growth factor receptor-2 (HER2)-negative early breast cancers with a novel type of anti-hormonal therapy, called an oral selective estrogen receptor degrader (SERD), led to clinically meaningful reductions in tumor activity prior to surgery.
› Verified 6 days ago
The patient survey data of At Home Healthcare is compared against the national average with the color code indicators: Better than National Average Worse than National Average| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percent of patients who reported that their home health team gave care in a professional way | 89 | 88 |
| Percent of patients who reported that their home health team communicated well with them | 83 | 85 |
| Percent of patients who reported that their home health team discussed medicines, pain, and home safety with them | 85 | 83 |
| Percent of patients who gave their home health agency a rating of 9 or 10 on a scale from 0 (lowest) to 10 (highest) | 83 | 84 |
| Percent of patients who reported YES, they would definitely recommend the home health agency to friends and family | 77 | 78 |
News Archive
PAREXEL Consulting, a business unit of PAREXEL International (Nasdaq: PRXL) and a leading global life sciences consultancy serving the biopharmaceutical and medical device industries, today released its second annual study on the state of the U.S. Food and Drug Administration (FDA) drug review process.
Taking aim at the fundamental biology of cancer cells, the National Institutes of Health has awarded $747,000 to Worcester Polytechnic Institute for a three-year research project to explore the molecular mechanisms associated with the genetic mutations and chromosome instability observed in all cancer cells.
HealthLeaders-InterStudy, a provider of managed care industry intelligence, reports hordes of area physicians are venturing enthusiastically into ownership of general acute-care hospitals with the vow to treat a full range of patients.
Early results from a UCLA-led clinical trial found treating women with estrogen receptor (ER)-positive and human epidermal growth factor receptor-2 (HER2)-negative early breast cancers with a novel type of anti-hormonal therapy, called an oral selective estrogen receptor degrader (SERD), led to clinically meaningful reductions in tumor activity prior to surgery.
› Verified 6 days ago
Alamosa County Public Health Department Location: 8900 Independence Way, Alamosa, Colorado 81101 Ratings: Phone: (719) 589-6639 | |
At Home Healthcare Location: 177 Craft Drive, Suite 100, Alamosa, Colorado 81101 Ratings: Phone: (719) 589-6425 |